Tue, January 17, 2012
Mon, January 16, 2012
Fri, January 13, 2012
[ Fri, Jan 13th 2012 ] - Market Wire
January 30, 2012
Thu, January 12, 2012
Wed, January 11, 2012
Tue, January 10, 2012
Mon, January 9, 2012
Sun, January 8, 2012
Sat, January 7, 2012
Fri, January 6, 2012
Thu, January 5, 2012
Wed, January 4, 2012
Tue, January 3, 2012

Omni Bio Pharmaceutical to Present at Noble Financial Capital Markets' Eighth Annual Equity Conference on January 18


//health-fitness.news-articles.net/content/2012/ .. ghth-annual-equity-conference-on-january-18.html
Published in Health and Fitness on Monday, January 9th 2012 at 6:07 GMT by Market Wire   Print publication without navigation


January 09, 2012 09:00 ET

Omni Bio Pharmaceutical to Present at Noble Financial Capital Markets' Eighth Annual Equity Conference on January 18

DENVER, CO--(Marketwire - Jan 9, 2012) - Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: [ OMBP ]), a clinical-stage biopharmaceutical company, today announced that it will present at Noble Financial Capital Markets' Eighth Annual Equity Conference being held January 17 & 18 at the Hard Rock Hotel & Casino in Hollywood, Florida.

Dr. James Crapo, Omni Bio's chief executive officer, is scheduled to speak on Wednesday, January 18 at 1:30 p.m. Eastern time (11:30 a.m. Mountain time).

Conference and presentation details will be made available at the Omni Bio website at [ www.omnibiopharma.com ]. An archived presentation will be available on the website for 30 days.

About Omni Bio Pharmaceutical, Inc.

Omni Bio Pharmaceutical, Inc. ([ www.omnibiopharma.com ]) is a clinical-stage biopharmaceutical company that has licensed potential new indications for an existing FDA approved drug -- Alpha‐1 antitrypsin (AAT). Omni Bio's core technology is based on issued patents and patent applications licensed from the University of Colorado Denver (UCD) and a privately held company, Bio Holding, Inc. Omni Bio's lead development program has been funding research and a human clinical trial to evaluate the effectiveness of AAT in the treatment of Type 1 diabetes. Novel discoveries made at UCD indicate that AAT has the potential to address a variety of indications in the areas of diabetes, transplant rejection and bacterial and viral disorders.

Omni Bio is also a significant investor in BioMimetix Pharmaceutical, Inc. (BioMimetix), a recently formed biopharmaceutical corporation. BioMimetix is the exclusive licensee of an issued patent held by Duke University, and intends to develop a new class of patented compounds for the treatment of various diseases including radiation toxicity during the treatment of cancer using radiation therapy.



Publication Contributing Sources